It is notable that TFAP2A levels are decreased in advanced-stage melanoma tumors versus earlier stage melanoma and nevi, whereas MITF expression levels are relatively constant (data from The Cancer Genome Atlas [46]). The gene discussed is TFAP2A; the disease is melanoma.